Company news
Context Therapeutics Inc. (NASDAQ:CNTX) news
Context Therapeutics Inc. news releases on 6ix. Latest, Sep 9, 2026: Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
Press releases & updates
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
September 9, 2026
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
August 5, 2026
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
July 6, 2026
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
June 15, 2026
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
May 27, 2026
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
May 18, 2026
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
May 6, 2026
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
April 1, 2026
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
March 22, 2026
Context Therapeutics to Participate in Upcoming Investor Conferences
February 9, 2026
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
November 7, 2025
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
November 5, 2025
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
October 6, 2025
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 3, 2025
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
August 6, 2025
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
June 2, 2025
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
May 29, 2025
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
May 7, 2025
Context Therapeutics Announces Chief Medical Officer Transition
May 5, 2025
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
April 30, 2025
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
April 9, 2025
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
March 26, 2025
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
March 25, 2025
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
March 20, 2025
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
January 13, 2025
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
January 12, 2025
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
November 5, 2024
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
October 15, 2024
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
September 22, 2024
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
September 3, 2024
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
August 6, 2024
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
July 31, 2024
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
July 9, 2024
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
May 7, 2024
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
May 1, 2024
Context Therapeutics Announces $100 Million Private Placement
May 1, 2024
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
March 31, 2024
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
March 20, 2024
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
November 8, 2023
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
October 30, 2023
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 26, 2023
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
August 8, 2023
Context Therapeutics to Participate in Two August 2023 Investor Conferences
July 31, 2023
Context Therapeutics Reports First Quarter 2023 Operating and Financial Results
May 9, 2023
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
March 21, 2023
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 14, 2023
Context Therapeutics announces positive responses in Phase 2 OATH clinical trial
February 6, 2023
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
February 5, 2023
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
January 8, 2023